Lead Opinion
Opinion for the court filed by Circuit Judge PROST. Concurring opinion filed by Circuit Judge BRYSON. Opinion concurring in part and dissenting in part filed by Circuit Judge RADER.
The United States Patent and Trademark Office (“USPTO”) appeals the April 1, 2008 decision of the United States District Court for the Eastern District of Virginia granting summary judgment that four recently promulgated rules exceed the scope of the USPTO’s rulemaking authority. Because we conclude that the four rules are procedural, but that Rule 78 is inconsistent with 35 U.S.C. § 120, we affirm-in-part, vacate-in-part, and remand.
I. BACKGROUND
In January 2006, the USPTO initiated two related notice and comment rulemak-ing proceedings. After receiving and considering the public comments, the USPTO issued the new rules on August 21, 2007, with an effective date of November 1, 2007. Changes to Practice for Continued Examination Filings, Patent Applications Containing Patentably Indistinct Claims, and Examination of Claims in Patent Applications, 72 Fed.Reg. 46,716 (Aug. 21, 2007). Four of the new rules (collectively, the “Final Rules”) are at issue in this appeal.
The two other rules, Final Rule 75 and Final Rule 265, are intended to address the USPTO’s difficulty in examining applications that contain a large number of claims. 72 Fed.Reg. at 46,721. Final Rule 75 requires an applicant who submits either more than five independent claims or twenty-five total claims to provide the examiner with information in an examination support document (“ESD”). 37 C.F.R. § 1.75(b)(1). The requirements for ESDs are set forth in Final Rule 265. To comply with Final Rule 265, an applicant must conduct a preexamination prior art search, provide a list of the most relevant references, identify which limitations are disclosed by each reference, explain how each independent claim is patentable over the referencеs, and show where in the specification each limitation is disclosed in accordance with 35 U.S.C. § 112, ¶ 1. Id. § 1.265(a).
Shortly after the Final Rules were published in the Federal Register, Triantafyllos Tafas, SmithKline Beecham Corporation, and Glaxo Group Limited (collectively, “Appellees”) filed suit against the USPTO. On October 31, 2007, the district court preliminarily enjoined enforcement of the Final Rules. Tafas v. Dudas,
The district court agreed with Appellees that the Final Rules were “substantive rules that change existing law and alter
The USPTO timely appealed. We have jurisdiction under 28 U.S.C. § 1295(a)(1).
II. DISCUSSION
“We review the district court’s grant of summary judgment without deference, reapplying the same standard as the district court.” Star Fruits S.N.C. v. United States,
The USPTO alleges two main errors in the district court’s analysis. First, the USPTO argues that the court erred by failing to give the agency’s interpretation of 35 U.S.C. § 2(b)(2)’s grant of rulemak-ing authority proper deference under Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc.,
A. The Scope of the USPTO’s Rulemaking Authority
Section 2(b)(2) of the Patent Act gives the USPTO authority to
*1352 establish regulations, not inconsistent with law, which ... (A) shall govern the conduct of proceedings in the office; ... (C) shall facilitate and expedite the processing of patent applications, particularly those which can be filed, stored, processed, searched, and retrieved electronically ... (D) may govern the recognition and conduct of agents, attorneys, or other persons representing applicants or other parties before the Office....
35 U.S.C. § 2(b)(2). Additionally, 35 U.S.C. § 132(b) requires the USPTO to “prescribe regulations to provide for the continued examination of applications for patent at the request of the applicant.” The USPTO asserts that this case should be fully resolved in its favor based on the language of these two sections. So long as the Final Rules fall within the scope of either § 2(b)(2) or § 132(b), the USPTO contends, they do not exceed its rulemak-ing authority. Further, the USPTO argues that this court has previously recognized that the USPTO’s interpretation of its rulemaking authority under § 2(b)(2) is entitled to Chevron deference. See, e.g., Lacavera v. Dudas,
1. The Substantive/Proeedural Distinction
We agreе with the district court that § 2(b)(2) “does not vest the USPTO with any general substantive rulemaking power.” Tafas II,
Additionally, when Merck was decided, 35 U.S.C. § 6(a) gave the USPTO authority to establish regulations that govern “the conduct of proceedings.” We agree with Appellees that Congress’s decision to replace § 6(a) with the current § 2(b)(2), which contains the same grant of authority to regulate “the conduct of proceedings in the Office” is indicative that Congress did not intend to give the USPTO substantive rulemaking authority.
Accordingly, we must reject the USP-TO’s argument that the substantive/procedural distinction is immaterial in this case.
2. Chevron Deference
The USPTO argues that the district court erred by failing to accord Chevron deference at two stages of its analysis. First, Chevron deference is allegedly required for the threshold question of whether § 2(b)(2) vests the USPTO with substantive rulemaking authority. Second, the USPTO maintains that its interpretation of variоus sections of the Patent Act, and its accordant belief that the Final Rules are consistent therewith, is also entitled to deference. We cannot accept the USPTO’s first argument, but we conclude that the USPTO’s interpretations of statutes that pertain to the USPTO’s delegated authority are entitled to Chevron deference.
Before a reviewing court grants Chevron deference, it must first determine whether the agency’s interpretation of the statute was made pursuant to “a congressional delegation of administrative authority.” Adams Fruit Co. v. Barrett,
We are not persuaded by the USPTO’s arguments in this case that Chevron deference should be extended to the issue of whether § 2(b)(2) provides substantive rulemaking authority. To the extent the USPTO relies on Federal Circuit cases that give Chevron deference to the USP-
The next question is the level of deference to be given to USPTO rules that are within the scope of the USPTO’s delegated authority, i.e., procedural rules promulgated under § 2(b)(2) or § 132(b). Our precedent is clear that the Chevron framework is applicable to review of these rules. See, e.g., Cooper Techs.,
B. Classification of the Final Rules
With the analytical framework established, we turn to whether the Final Rules are substantive or procedural. The parties agree that the USPTO has authority under § 2(b)(2) to promulgate procedural rules. They vigorously disagree, however, as to how the boundary between “substantive” and “procedural” rules should be defined.
The district court relied on Chrysler Corp. v. Brown,
In addition to Chrysler, the parties cite several cases from the D.C. Circuit that have addressed the boundaries of substantive rules.
We are most persuaded in this case by the D.C. Circuit’s approach in JEM. At issue in that case were “hard look” rules adopted by the Federal Communications Commission (“FCC”) in response to a significant number of “carelessly prepared and speculative applications” for broadcasting licenses.
While we do not purport to set forth a definitive rule for distinguishing between substance and procedure in this case, we conclude that the Final Rules challenged in this case are procedural. In essence, they govern the timing of and materials that must be submitted with patent applications. The Final Rules may “alter the manner in which the parties present ... their viewpoints” to the USPTO, but they do not, on their face, “foreclose effective opportunity” to present patent applications for examination. JEM,
Final Rules 78 and 114 provide requirements for when continuation applications will be accepted and RCEs will be granted. The D.C. Circuit has recognized time schedules as being “definitely at the procedural end of a spectrum running from ‘procedural’ to ‘substantive.’ ” Lamoille,
We are of course aware that the impact of Final Rules 78 and 114 will be largely dependent on how the USPTO interprets when amendments, arguments, and evidence “could not have been submitted during the prosecution of the prior-filed application” or “prior to the close of prosecution.” 37 C.F.R. §§ 1.78, 1.114(g). When the Final Rules were published, the USPTO also published responses to questions raised during the notice and comment proceedings, many of which addressed specific scenarios under which continuation applications and RCEs may be requested. See, e.g., 72 Fed.Reg. at 46,769-77. The district court relied on the contents of these responses to conclude that the USPTO “intends to deny additional applications in almost all circumstances” such that Final Rules 78 and 114 are in fact “hard limits” on continuation applications and RCEs. Tafas II,
With respect to the ESD requirement, Final Rules 75 and 265 require applicants who present more than five independent claims or twenty-five total claims to provide the examiner with information about the prior art and why they believe the claims are patentable over it. Once a satisfactory ESD is submitted, examination will proceed in precisely the same manner as it would have in the absencе of the rule. It is important to note that an examiner is not permitted to substantively reject claims on grounds that the ESD did not prove that the claims are patentable. While an examiner is of course free to base a rejection on references disclosed in the ESD, he must nevertheless set forth his own prima facie case of unpatentability. Thus, while the rule may put a burden of production on the applicant, the examiner maintains the burden of persuasion.
This court has previously recognized the validity of two USPTO rules that place upon applicants the burden of submitting information in response to an examiner’s request. See Star Fruits,
Appellees and amici argue that the ESD requirement is in fact so draconian that compliance would be both impossible and extraordinarily foolish. With respect to impossibility, Appellees argue that Rule 265 requires a “world-wide search of prior art without regard to scope, time, or cost.” GlaxoSmithKline Br. 46. We do not find such a requiremеnt on the face of Final Rule 265. Rather, the rule describes a preexamination search of “U.S. patents and patent application publications, foreign patent documents, and non-patent literature,” and requests specific details about the scope of the search. 37 C.F.R. § 1.265(a)-(b). The text of the rule does not demand that the applicant review every reference that fits into one of those categories, regardless of its location or accessibility. Instead, it requires applicants to conduct and document a “search.” A “search” of “non-patent literature” does not necessarily require a visit to every library in every corner of the world. A reasonable, cost-effective search is just as much a “search” as the search described by Appellees. While the text of the rules sets forth a facially reasonable procedural requirement,
Search scope aside, several amici argue that submitting an ESD is so wrought with peril that sane applicants will be absolutely limited to five independent claims and twenty-five total claims. These arguments have two components. The first is that even the most diligently prepared ESD will inevitably open the applicant to inequitable conduct allegations that will entail costly litigation and a possible finding of unenforceability. We believe this concern is too speculative to void the rules and, in any event, is at its core a matter of inequitable conduct doctrine, not USPTO rulemaking authority. The reach of inequitable conduct is solely within the control of the courts, and the doctrine has obviously not yet been applied in the context of an ESD. We decline to decide that an otherwise valid USPTO rule that requires applicants to provide information is void because this court might in the future apply inequitable conduct doctrine in such a way that honest applicants who comply in good faith will nevertheless lose their patent rights. Under Kingsdown Medical Consultants, Ltd., v. Hollister, Inc., “ ‘gross negligence’ does not of itself justify an inference of intent to deceive.”
Second, several amici argue that ESDs will decrease the value of patent rights because the statements therein will limit claim scope through prosecution history estoppel. We do not believe applicants have a right to remain silent throughout prosecution in order to maximize their advantage in later litigation. The Patent Act demonstrates that applicants are expected to be forthright about their inventions. Section 112 requires applicants to provide a “written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art ... to make and use the same.” 35 U.S.C. § 112, ¶ 1 (emphasis added). It also requires the application to “conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” Id. § 112, ¶ 2 (emphasis added). This court has recognized that “[applicants for patents have a duty to prosecute patent applications in the Patent Office with candor, good faith, and honesty.” See Honeywell Int’l Inc. v. Universal Avionics Sys. Corp.,
C. Consistency with the Patent Act
We address here the specific conflicts that the district court identified and relied upon in its opinion. Because each of the rules is procedural, we must, as discussed above, give Chevron deference to the USPTO’s interpretation of the provisions of the Patent Act that relate to “proceedings in the Office.” Cooper Techs.,
1. Final Rule 78
The district court found that Final Rule 78’s requirement for the third and subsequent continuation applications was inconsistent with the text of 35 U.S.C. § 120 and this court’s precedent. Section 120, with emphasis and bracketed enumeration added, provides that:
An application for patent for [1] an invention disclosed in the manner provided by the first paragraph of section 112 of this title in an application previously filed in the United States, or as provided by section 363 of this title, which is [2]*1360 filed by an inventor or inventors named in the previously filed application shall have the same effect, as to such invention, as though filed on the date of the prior application, [3] if filed before the patenting or abandonment of or termination of proceedings on [3a] the first application or on [3b] an application similarly entitled to the benefit of the filing date of the first application and [4] if it contains or is amended to contain a specific reference to the earlier filed application. No application shall be entitled to the benefit of an earlier filed application under this section unless an amendment containing the specific reference to the earlier filed application is submitted at such time during the pendency of the application as required by the Director. The Director may consider the failure to submit such an amendment within that time period as a waiver of any benefit under this section. The Director may establish procedures, including the payment of a surcharge, to accept an unintentionally delayed submission of an amendment under this section.
The district court concluded that Final Rule 78 was inconsistent with the statutory mandate that qualifying applications “shall have” the benefit of the priority date of the initial application. Tafas II,
We agree with the district court that Final Rule 78 is inconsistent with § 120, although we rely on narrower grounds. Section 120 unambiguously states that an application that meets four requirements “shall have the same effect, as to such invention, as though filed on the date of the prior application.” 35 U.S.C. § 120 (emphasis added). These requirements, which correspond to the bracketed enumeration above, include [1] the invention claimed in the application must have been properly disclosed in a prior-filed application; [2] the application must have been filed by inventor(s) named on the prior-filed application; [3] the application must have been “filed before the patenting or abandonment of or termination of proceedings on the first application or on an application similarly entitled to the benefit of the filing date of the first application”; and [4] the application must contain or be amended to contain a specific reference to the prior-filed application. The use of “shall” indicates that these are the exclusive requirements, and that all applications that meet these requirements must receive the benefit provided by § 120. See Transco Prods., Inc. v. Performance Contracting, Inc.,
As amici, several intellectual property and administrative law professors argue that Henriksen expressly recognized ambiguity in § 120. Accordingly, they argue, the USPTO’s interpretation is entitled to deference under Brand X. We agree that the Henriksen court’s approach of delving into the legislative history, which it noted was “somewhat inconclusive,” indicates that the text of the statute contains some ambiguity. See Henriksen,
Finally, the USPTO’s reliance on In re Bogese,
2. Final Rule 114
The district court found that Final Rule 114, which governs the availability of RCEs, conflicts with the Patent Act in two ways. The first was that it “places a limit on RCEs as of right on the basis of application family, rather than on the basis of each individual application, whether it be a parent application or a continuation or continuation-in-part application.” Tajas II,
We do not find that § 132 unambiguously dictates that its provisions be applied on a per application basis. Cf. Henriksen,
Appellees next argue that the use of “shall” in conjunction with the phrase “at the request of the applicant” in § 132(b) clearly shows that Congress intended RCEs to be unlimited and subject only to the applicant’s discretion. GlaxoSmithK-line Br. 40. We do not find the statute so clear. It is plausible that, as the USPTO suggests, § 132(b) simply directs the USP-TO to “prescribe regulations” to govern the applicant’s ability to request continued examination which must, in some circumstances, be granted. Under this reading, nothing prevents the USPTO from limiting the availability of the second and subsequent RCEs. Because § 132(b) does not unambiguously require the USPTO to grant unlimited RCEs, we defer to the
Finally, Appellees argue that § 132(a) requires the USPTO to continue examination if “the applicant persists in his claim for a patent.” Tafas Br. 32-33. Section 132(a) provides:
Whenever, on examination, any claim for a patent is rejected, or any objection or requirement made, the Director shall notify the applicant thereof, stating the reasons for such rejection, or objection or requirement, together with such information and references as may be useful in judging of the propriety of continuing the prosecution of his application; аnd if after receiving such notice, the applicant persists in his claim for a patent, with or without amendment, the application shall be reexamined. No amendment shall introduce new matter into the disclosure of the invention.
35 U.S.C. § 132(a) (emphases added). The USPTO responds that this argument “reflects a misunderstanding of the relationship between subsections (a) and (b) [of § 132].” USPTO Br. 53. According to the USPTO, “[sjubsection (a) provides for the ‘reexamination’ of an application at the applicant’s request after the initial examination provided in section 131. In contrast, ‘continued examination’ under subsection (b) occurs after the reexamination provided for in subsection (a) is complete.” Id. Section 132 does not define the difference between “continued examination” and “reexamination.” Because we find the USPTO’s explanation reasonable, we defer to its interpretation that § 132(a) does not require it to grant unlimited RCEs. See Cooper Techs.,
3. Final Rules 75 and 265
The district court held that the ESD requirement violated 35 U.S.C. §§ 102, 103, 112, and 131, as well as this court’s precedent that holds that applicants have no duty to search the prior art. The court began its analysis with § 112, ¶ 2’s requirement that “[t]he specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” The district court held, and Appellees argue on appeal, that this language precludes the USPTO from putting an arbitrary limit on the number of claims in an application.
Subject to the arguable requirement that an applicant cannot “obscure” his invention by “undue multiрlicity,” our precedent does not suggest that there is a limit on the number of claims. In re Clark,
The district court also found that Final Rules 75 and 265 went too far by requiring applicants to “conduct a broad search of patents, patent applications, and literature, and provide, among other things, a ‘detailed explanation’ of ‘how each of the independent claims is patentable over the cited references.’ ” Tafas II,
Finally, the district court found that Final Rules 75 and 265 improperly shift the burden away from the examiner and onto the applicant. Tafas II,
III. CONCLUSION
For the foregoing reasons, we conclude that the Final Rules 75, 78, 114, and 265 are procedural rules that are within the scope of the USPTO’s rulemaking authority. However, we find that Final Rule 78 conflicts with 35 U.S.C. § 120 and is thus invalid. Accordingly, we affirm the district court’s grant of summary judgment that Final Rule 78 is invalid, vacate its grant of summary judgment with respect to Final Rules 75, 114, and 265, and remand for further proceedings consistent with this opinion.
COSTS
Each party shall bear its own costs.
AFFIRMED-IN-PART, VACATED-IN-PART, AND REMANDED
Notes
. For a discussion of the problems created by continuation applications, see Mark A. Lemley & Kimberly A. Moore, Ending Abuse of Patent Continuations, 84 B.U. L.Rev. 63, 71-83 (2004).
. The district court fully disposed of the case on the grounds that the Final Rules are substantive. As part of its analysis, the court partially considered whether the rules conflict with the law. Apart from this, the court did not address Appellees’ other arguments.
. While Cooper Technologies,
. The concurrence and dissent each correctly point out that this is not a case arising under the notice and comment rulemaking provision of the APA. Therefore, this case does not turn on whether the rules are "procedural” within the meaning of 5 U.S.C. § 553(b)(A). We recognize that the definitions of "substance” and "procedure” in the notice and comment rulemaking context may embody policy considerations that are not coextensive with the considerations at issue in this case. However, we find that these cases are nevertheless helpful to the task of drawing a similar line between "substance” and "procedure” in the present case.
. To the extent the USPTO has commented about its intended application of the ESD requirement, either in public speeches or in ble Federal Register, we make the same observation made above: these comments do
Concurrence Opinion
concurring.
I join Judge Prost’s opinion but with the following observations.
1. In my view, the question whether the PTO is authorized to promulgate particular regulations does not turn on an abstract inquiry into whether a particular rule can be characterized as substantive, procedural, or interpretive. Instead, it calls on us to ask what Congress has empowered the PTO to do through rulemak-ing. Congress has not used the broadest available language in the statute that authorizes the PTO to engage in rulemaking, but neither has it used the narrowest. Congress could have authorized the PTO to issue any regulations that are necessary or appropriate to administer the patent laws. See, e.g., 38 U.S.C. § 501 (Secretary of Veterans Affairs authorized to prescribe “all rules and regulations which are neces-, sary or appropriate to carry out the laws administered by the Department”); 5 U.S.C. § 8347(a) (Office of Personnel Management given authority to prescribe “such regulations as are necessary and proper to carry out [the Civil Service Retirement Act]”). Language of that sort would have given the PTO the very broad rulemaking authority. On the other hand, the PTO could have given no special authority to promulgate regulations, which would have had the effect of limiting the PTO to the narrow scope of 5 U.S.C. § 301, which allows all agencies to prescribe regulations “for the government of ... [the] department, the conduct of its employees, the distribution and performance of its business, and the custody, use, and preservation of its records, papers, and property.” Congress did neither. Instead, it charted a middle course in 35 U.S.C. § 2(b), permitting the agency somewhat broader regulatory powers than are contemplated by section 301, but narrower than the broad “necessary or appropriate” rulemaking authority given to some other agencies.
Section 2(b)(2)(A) of the Patent Act vests the PTO with authority to promulgate regulations that “govern the conduct of proceedings in the Office.” The subject matter that most clearly falls within the scope of that provision is the admission and discipline of attorneys practicing before the PTO. See, e.g., Bender v. Dudas,
For essentially the reasons given by the majority opinion and in light of the above-cited authorities, I am satisfied that the regulations in this case are of the type that Congress authorized in section 2(b) of the Patent Act, as that provision has been construed by this court. While I think it is generally fair to characterize that statute as authorizing the promulgation of “procedural” regulations, however, I do not think it necessary, or particularly helpful, to consider whether those regulations would be deemed “substantive,” “interpretive,” or “procedural” either under section 4 of the Administrative Procedure Act, 5 U.S.C. § 553, or under statutory schemes applicable to other agencies.
The same approach seems to me to be called for in deciding whether the agency is entitled to deference with respect to the scope of its own authority. There, too, the issue comes down to one of statutory construction — whether Congress left the boundaries of agency authority undefined and subject to refinement through the exercise of agency expertise, or whether Congress established a firm line, enforceable by courts, beyond which the agency could not venture. Normally, Congress defines the field of agency rulemaking authority in unambiguous terms that are readily applied by courts, so there is little reason to resort to Chevron-type analysis. In some instances, however, Congress has defined the agency’s rulemaking jurisdiction using vague terms, or terms that call for agency interpretation, or even terms that expressly leave the scope of rulemak-ing authority to the agency to decide; in those cases, deference to the agency may be appropriate or even necessary. See, e.g., Bender v. Dudas,
Because I agree with Judge Prost that the challenged regulations are within the scope of the authorization that Congress granted to the PTO in section 2(b), I likewise conclude that the issue in this case comes down to whether the challenged regulations are consistent with other provisions of the Patent Act.
2. On the merits, the most difficult question in this case for me is whether Final Rule 78 is a valid regulation in light of 35 U.S.C. § 120. My colleagues conclude that it is invalid, although for different reasons. I agree that it is invalid for the reasons given by Judge Prost, al
The court holds that Final Rule 78 is invalid because it limits the number of continuation applications that may be filed and applies that limit even if all of the continuation applications are filed while the first application is still pending. Section 120 plainly provides that any application that satisfies the other requirements of the statute and is “filed before the patenting or abandonment of or termination of proceedings on the first application” shall have the same effect “as though filed on the date of the prior application.” 35 U.S.C. § 120. Therefore, a rule limiting the number of continuances co-pending with the first-filed application is necessarily contrary to the statute and invаlid.
While that is a sufficient reason to invalidate Final Rule 78, it does not answer the question whether the rule is invalid as applied to serial continuances, i.e., a series of continuances in which each was co-pending with its immediate predecessor, but in which only the second in the series was co-pending with the first application. Under current law, all continuances in such a series, if they satisfy the other requirements of section 120, are deemed to have the same effective date as the first application. Rule 78 would change that practice.
The question whether the new Rule’s restrictions on serial continuances would also be invalid is more complex than the question of the validity of restrictions on co-pending applications. As to serial continuances, section 120 provides that an application for continued prosecution is entitled to the benefit of an earlier priority date when it is co-pending with “an application similarly entitled to the benefit of the filing date of the first application.” For the last 40 years, that portion of section 120 has been understood to confer upon patent applicants the right to file any number of successive continuation applications after the first application has been abandoned or issued as a patent. That was the construction of section 120 that our predecessor court adopted in 1968, overturning a Patent Office Board of Appeals decision to the contrary. In re Henriksen,
The court today properly strikes down Final Rule 78 because its restrictions on co-pending, or parallel, continuations is contrary to the plain language of section 120, which provides that such a co-pending continuation “shall” be given the same priority date as the original application and which contains no restriction on the numbers of such applications that are permitted. That is not to say, however, that a revised rule that addressed only serial con
Concurrence Opinion
concurring in part and dissenting in part.
I concur with this court’s conclusion that the PTO is not entitled to Chevron deference with respect to its own rulemaking authority. However, in my view, the Final Rules are substantive, not procedural. Thus, I would affirm the district court’s conclusion that the PTO exceeded its statutory rulemaking authority in promulgating these rules. For that reason, I concur in part with this court’s ultimate conclusion regarding Final Rule 78, but dissent in part with respect to Final Rules 114, 75, and 265.
This case presents a threshold question about the nature of these rules- — substantive or procedural. The organic act of the PTO “does NOT grant the Commissioner the authority to issue substantive rules.” Merck & Co. v. Kessler,
The distinction between substantive or non-substantive rules requires a difficult judgment. This distinction arises most often in the context of interpreting the exception to the requirement for notice and comment procedures in the Administrative Procedure Act (“APA”). 5 U.S.C. § 553(b)(A). In the most common scenario, an agency has promulgated a rule without undergoing the strictures of notice and comment rulemaking. The reviewing court must then, when necessary, apply the APA’s exemption for “interpretative rules, general statements of policy, or rules of agency organization, procedure, or practice.” Id. In other words, the courts may only sustain non-substantive rulemak-ing in those cases. See, e.g., Animal Legal Def. Fund v. Quigg,
The instant case, however, presents a different situation. These PTO rules have no procedural defects. Instead, this case asks this court to ensure that the PTO has not exceeded its rulemaking authority. Thus, in the present context, this court misapplies the teachings of cases such as Animal Legal Defense Fund and Cooper Technologies Co. v. Dudas,
The Supreme Court provided valuable guidance on the substantive/nonsubstan-tive inquiry in Chrysler Corp. v. Brown,
Both this court and the Court of Appeals for the District of Columbia Circuit have relied on Chrysler in building a body of jurisprudence germane to the substantive/nonsubstantive inquiry. Central to this jurisprudence is the recognition that classifying a rule as substantive or non-substantive is a case-by-case exercise, poorly suited for bright-line rules. See, e.g., Bowen,
No doubt, the Chrysler Court’s inquiry — whether a rule “affects individual rights and obligations” — if analyzed in a vacuum, would blur the line between substantive and non-substantive rules. See, e.g., Bowen,
To my eyes, this question of degree must guide this court’s assessment of the substantive nature of the PTO’s Final Rules. This court has confronted that question before and gauged a rule’s impact on parties’ rights and obligations by examining the rules’ changes to existing law or policy. See, e.g., Cooper Techs.,
The D.C. Circuit’s 1999 decision in Chamber of Commerce is particularly instructive.
Implicit in the majority’s holding that the Final Rules are procedural is that the rules fit within the “procedural” exception to the APA’s notice and comment requirement. Yet applying this logic, the PTO would never be subject to the APA’s notice and comment procedures because it only has statutory authоrity to promulgate rules that fall within exceptions to notice and comment, i.e., non-substantive rules. Here, the PTO provided a notice and comment period. In other words, the PTO recognized that “the policies promoted by public participation in rulemaking ... out-weighted] ... countervailing considerations of effectiveness, efficiency, expedition and reduction in expense.” See Guardian Federal,
II
Contrary to this court’s holding today, the Final Rules are not “incidental inconveniences of complying with an enforcement scheme.” The Final Rules are substantive. The Final Rules affect individual rights and obligations, and mark a startling change in existing law and patent policy. As the district court correctly noted,
The 2 + 1 Rule and the 5/25 Rule, which limit continuing applications, RCEs, and claims, and the ESD requirement, which shifts the examination burden onto applicants, constitute a drastic departure from the terms of the Patent Act as they are presently understood. By so departing, the Final Rules effect changes in GSK’s and Tafas’s existing rights and obligations.
Tafas v. Dudas,
A. Final Rule 78
Final Rule 78 restricts to two the number of continuation applications entitled to an earlier priority date, unless the applicant files a petition showing that the amendment, argument, or evidence could not have been submitted during the prosecution of the prior-filed application (“petition and showing”). As this court notes today, that rule contravenes the language of 35 U.S.C. § 120. The statute is clear: later filed continuation applications “shall have the same effect, as to such invention, as though filed on the date of the prior application.” 35 U.S.C. § 120 (emphasis added). Final Rule 78 is not “a prospective clarification of ambiguous statutory language regarding a matter of procedure,” Cooper Techs.,
In fact, this court’s predecessor considered the language of 35 U.S.C. § 120: “[T]here is no statutory basis for fixing an arbitrary limit to the number of [continuing] applications” that can retain the benefit of the priority date. In re Henriksen,
The Office argues that Final Rule 78 is not substantive because the petition and showing requirement provides an alternative avenue for seeking additional continuations. The PTO’s argument admits far too much. In order to receive the benefit of priority for later-filеd continuation applications, which was previously available as a matter or right, the applicant must now justify the right with further showings. This new “petition and showing” hurdle is neither required nor contemplated by § 120. In mechanically applying only one statement from JEM, the majority opinion ignores that the “substantive effect” of failing to meet this new obligation — the loss of priority date — is “suffi
B. Final Rule 114
The same holds true with respect to Final Rule 114, imposing a limit of one request for continued examination (“RCE”) per application family. The American Inventor’s Protection Act of 1999 stated that the RCE provisions “shall apply to all applications” filed on or after June 8, 1995. The Act did not impose or contemplate a restrictive RCE practice. To the contrary, subject to the doctrine of prosecution laches, applicants could file an RCE as a matter of right.
The impact and reach of the Final Rules 78 and 114 (“the 2 + 1 Rule”) significantly affects patent prosecution. Several amicus briefs point out reasonable scenarios where an applicant may choose to file an RCE during prosecution, e.g., in order to provoke an interference, to clarify claim scope in anticipation of litigation, and to submit an information disclosure statement (“IDS”). Yet these Final Rules could interfere with those reasonable scenarios.
By way of example, consider the following scenario: An applicant receives a Notice of Allowance for application A. Before paying the issue fee, the applicant discovers a material prior art reference in a foreign appliсation. Mindful of the duty to disclose material information to the Office, that applicant would file an RCE, an IDS citing the reference, and an amendment to account for the newly discovered prior art. So far so good, but what if the reference is not only material to application A, but also material to continuation applications B and C, members of the same application family that have also received Notices of Allowance? Under the 2 + 1 Rule, the applicant would have exhausted the two continuations and one RCE. What happens to applications B and C? Even if the submission of newly-discovered prior art satisfied the “petition and showing” requirement (which the PTO has said it will likely not), the “petition and showing” requirement is legislative because it imposes a new burden on the inventor. Because they require “more than adherence to existing law,” Final Rules 78 and 114 are substantive. See Chamber of Commerce,
C. Final Rule 75
Final Rule 75 limits an application to five independent claims or twenty-five claims total. Placing an arbitrary limit on the number of claims in an application drastically affects an applicant’s rights and obligations under the Patent Act. To be specific, this rule alters obligations under 35 U.S.C. §§ 102, 103, 112, and 131. For instance, § 112, ¶2 requires that “[t]he specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” 35 U.S.C. § 112, ¶ 2 (emphasis added). Placing a mechanical cap on the number of claims in an application hinders an applicant’s right (and obligation) to “particularly [point] out and distinctly [claim] the subject matter which the applicant regards as his invention.” Id. Indeed, “one or more claims” suggests at least one, not а ceiling to the number of claims in an application. Once again, if the Act wished to specify an upper limit on the number of claims, it could do so right at this point. Instead the “or more” requirement places no limit on the number of claims. The Act instead articulates a clear policy in favor of allowing as many claims as an applicant is willing to pay for.
As the majority opinion acknowledges, this court’s precedent suggests no limit on the number of claims. See In re Wakefield,
By analogy, this rule has a similar effect to imposing a five-page limit on applications. Although that notion is obviously too simplistic and problematic, this court’s rationale would apparently make that hypothetical rule possible as a procedural rule that merely “[alters] the manner in which the parties present themselves or their viewpoints to the agency.” JEM,
Likewise, limiting an applicant to five independent claims ignores the varying scopes and methods of claiming inventions across different technologies. For example, in a pharmaceutical application, an applicant may claim not only the genus compound, but also a number of species, intermediates, methods of making, and methods of use. Asking an inventor to limit her application to five independent claims disproportionately affects technologies with greater complexity and greater public interest in disclosure. See Neighborhood TV,
This court today forgets that an inventor’s incentive to disclose is commensurate with the protection available. With less ability to claim myriad methods of making, methods of use, species and intermediates, and more, an inventor will have less incentive to disclose the full dimension of the technological advance. Final Rule 75 frustrates the quid pro quo contemplated by the Patent Act.
D. Final Rule 265
On appeal, the PTO submits that limiting an application to five independent claims, or twenty-five claims total, is not a mechanical limitation, but just a trigger to the requirement to file an Examination Support Document (“ESD”). Final Rule 265 goes too far, however, by requiring an applicant to “conduct a broad search of patents, patent applications, and literature, and provide, among other things, a ‘detailed explanation’ of ‘how each of the independent claims is patentable over the cited references.’ ” Tafas,
Section 102 provides “[a] person shall be entitled to a patent unless ” and section 131 provides that “[t]he director shall cause an examination to be made of the application.” 35 U.S.C. §§ 102, 131. Thus, the PTO bears the burden of putting forth a prima facie case of unpatentability. See In re Oetiker,
This shift of the burden of proof (or production, for that matter) onto the applicant significantly alters practice before the PTO and represents “a change in existing law or policy.” Animal Legal Def. Fund,
Ill
Because the Final Rules drastically change the existing law and alter an inventor’s rights and obligations under the Patent Act, they are substantive and the PTO exceeded its statutory rulemaking authority under 35 U.S.C. § 2(b)(2). For the reasons stated above, I would affirm.
